Vizsgálati helyszín
Fundació ACE, Institut Català de Neurociències Aplicades
Barcelona, 08028, SpanyolországMég nincs intézményhez kötve
- 17futó vizsgálat
- 15lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 33 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 2. fázis18 vizsgálat
- 3. fázis10 vizsgálat
- 1. fázis2 vizsgálat
- 1/2. fázis2 vizsgálat
- Állapot
- Lezárult15 vizsgálat
- Fut, nem toboroz9 vizsgálat
- Toboroz6 vizsgálat
- Még nem toboroz2 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- Hoffmann-La Roche4 vizsgálat
- Eisai Inc.2 vizsgálat
- Eli Lilly and Company2 vizsgálat
- F. Hoffmann-La Roche AG2 vizsgálat
- Glaxosmithkline Research & Development Limited2 vizsgálat
- és még 19
Futó vizsgálatok
Toboroz
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
NCT07781657· 2. fázis· Hoffmann-La Roche· Forrás
Még nem toboroz
A study to learn about the effects of Trontinemab in participants at risk for Alzheimer‘s disease
2025-524314-29-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás
Toboroz
A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
NCT07688213· 2. fázis· Sanofi· Forrás
Toboroz
Brain imaging to understand early changes in dementia related diseases
2025-523284-37-00· 2. fázis· Barcelonabeta Brain Research Center· Forrás
Toboroz
InRAD Observational Study
NCT07213700· Stichting International Registry for Alzheimer's Disease and other Dementias Foundation· Forrás
Contact: Mercè Boada (principal investigator)
Fut, nem toboroz
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
NCT07033494· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
NCT06653153· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A study to evaluate the safety and long-term biomarker effects of RO7269162 in participants at risk for or at the prodromal stage of Alzheimer’s Disease (AD)
2023-506183-13-00· 2. fázis· F. Hoffmann-La Roche AG· Forrás
Fut, nem toboroz
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
NCT05531526· 3. fázis· AriBio Co., Ltd.· Forrás
Fut, nem toboroz
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
NCT05508789· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888· 2. fázis· Biogen· Forrás
Toboroz
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106· 1/2. fázis· AC Immune SA· Forrás
Fut, nem toboroz
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
NCT04639050· 1/2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
NCT04468659· 3. fázis· Eisai Inc.· Forrás
Fut, nem toboroz
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
NCT03887455· 3. fázis· Eisai Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease
2024-516966-12-00· 2. fázis· Novartis Pharma AG· Forrás
Fut, nem toboroz
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
NCT07234942· 1. fázis· Hoffmann-La Roche· Forrás
Lezárult
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease.
2025-521107-42-00· 2. fázis· Glaxosmithkline Research & Development Limited· Forrás
Lezárult
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia
2024-515539-31-00· 2. fázis· Merck Sharp & Dohme LLC· Forrás
Lezárult
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE
NCT06079190· 2. fázis· Glaxosmithkline Research & Development Limited· Forrás
Lezárult
Open-Label Extension Study of PRX012 in Subjects with Alzheimer’s Disease Who Were Enrolled in Study PRX012-101 or PRX012-102
2023-503729-20-00· 1. fázis· Othair Prothena Limited· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
NCT06335173· 2. fázis· Acumen Pharmaceuticals· Forrás
Lezárult
Study to Assess Safety and Efficacy of PRI-002 in Patients With MCI to Mild Dementia Due to Alzheimer's Disease (AD)
NCT06182085· 2. fázis· PRInnovation GmbH· Forrás
Lezárult
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alzheimer’s disease (AD)
2022-503148-41-00· 2. fázis· Prinnovation GmbH· Forrás
Lezárult
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
NCT05189210· 2. fázis· GemVax & Kael· Forrás
Lezárult
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
NCT05291234· 2. fázis· AbbVie· Forrás
Lezárult
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
NCT04867616· 2. fázis· UCB Biopharma SRL· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease
2022-501188-42-00· 2. fázis· Janssen - Cilag International· Forrás
Hibát jelzek